B+
Bull case
25%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-09-30 · RankAlpha Sentiment Codex
MNKD
MannKindCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
ReadyFlow and pediatric Afrezza adoption could diversify revenue while MNKD-201 and ralinepag DPI advance. Q2 revenue grew 43% to $109.4 million, although acquisition-related FUROSCIX revenue contributed to that growth.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -5.8.
What can break
A director reported open-market sales in August and September; these transactions do not establish an operating deterioration. [#SEC-FORM4-2026-09-28]
Momentum
21
Value
50
Sentiment
62
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.40 · Bull $4.50 · Bear $2.30Analysis 2026-09-30; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-30 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $8.08
Why
Momentum21 · Δ7d -8.5
Value50 · Δ7d -0.2
Sentiment62 · Δ7d -5.8
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -5.8.
Contradictions & invalidation
- • A director reported open-market sales in August and September; these transactions do not establish an operating deterioration. [#SEC-FORM4-2026-09-28]
- • Afrezza Q2 sales declined 7% year over year despite early pediatric prescribing; prescription persistence and payer conversion remain uncertain. [#SEC-8K-2026-08-05]
- • Q2 Afrezza sales declined year over year, commercial-launch and R&D spending increased, and FUROSCIX economics and payer uptake remain uncertain.
Catalyst clock
2026-12-31
Afrezza pediatric adoption
Lead driver: Sentiment · See AI snapshot
Momentum
21
8% active weight
Current posture
7d trendSoftening
Δ7d
-8.5
Δ21d
+0.7
Value
50
47% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.6
Sentiment
62
45% active weight
Current posture
7d trendSoftening
Δ7d
-5.8
Δ21d
+13.3
Why this grade
Composite grade C. Momentum 21.0 / Value 50.2 / Sentiment 62.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-30. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$3.40
Analysis reference price unavailable
Analysis 2026-09-30 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$2.30
Analysis reference price unavailable
Analysis 2026-09-30 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$1.03B
Beta
0.84
Shares Out
321.55M
P/E (TTM)
60.7
P/S (TTM)
5.50
P/FCF (TTM)
39.77
Rev YoY
+42.9%
EPS YoY
-3033.3%
Gross Margin
+72.2%
Op Margin
+3.4%
Net Debt
$302.04M
Current Ratio
1.72
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data